- Patient Information:
Details with Side Effects
Lexiscan® (regadenoson) injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.
DOSAGE AND ADMINISTRATION
The recommended intravenous dose of Lexiscan is 5 mL (0.4 mg regadenoson)
- Administer Lexiscan as a rapid (approximately 10 seconds) injection into a peripheral vein using a 22 gauge or larger catheter or needle.
- Administer a 5 mL saline flush immediately after the injection of Lexiscan.
- Administer the radionuclide myocardial perfusion imaging agent 10–20 seconds after the saline flush. The radionuclide may be injected directly into the same catheter as Lexiscan.
NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer Lexiscan if it contains particulate matter or is discolored.
Dosage Forms And Strengths
- Single-use pre-filled syringe: Injection solution containing regadenoson 0.4 mg/5 mL (0.08 mg/mL).
Storage And Handling
Lexiscan is supplied as a sterile, preservative-free solution containing 0.08 mg/mL regadenoson in the following package:
Single-use 5 mL pre-filled plastic Ansyr® syringes with luer-lock fitting (NDC 0469-6501-89).
Store at controlled room temperature, 25°C (77°F); excursions permitted to 15° to 30°C (59°–86°F).
Marketed by: Astellas Pharma US, Inc. Northbrook, IL 60062. Syringes Manufactured by: Hospira, Inc. Lake Forest, IL 60045 USA. Revised: October 2013 13G036-LEX
Last reviewed on RxList: 1/21/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Lexiscan Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.